Novartis is building a new radioligand plant in China
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Category: Pharma
STAT+: Pharmalittle: Roche to buy obesity-drug developer for $2.7 billion; Novo Nordisk paid U.S. doctors $26 million over a decade
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
.jpg)
STAT+: Roche to acquire obesity-focused Carmot Therapeutics for $2.7 billion
LONDON — The booming obesity market is attracting another player, as pharma giant Roche said…
Johnson & Johnson bets heavy on AI-driven drug discovery
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Pfizer halts development of twice-daily obesity pill; Supreme Court to review Purdue bankruptcy deal
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pfizer to halt development of its twice-daily oral obesity drug, following disappointing trial
Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after…
STAT+: U.S. Supreme Court to review controversial Purdue Pharma bankruptcy settlement
After weeks of anticipation, the U.S. Supreme Court on Monday will hear arguments to decide…
STAT+: Texas AG accuses Pfizer of ‘intentionally’ overstating Covid-19 vaccine effectiveness
The Texas attorney general has filed a lawsuit accusing Pfizer of “unlawfully” and “intentionally” misrepresenting…
Do GLP-1s have a future treating alcoholism?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: AbbVie buys Immunogen, maker of targeted cancer drugs; Novo sues two more compounders
Rise and shine, everyone, another busy day is on the way. We can tell because…
Flagship Pioneering crosses the pond, opens a European front
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: FDA probes CAR-T therapy for links to lymphoma; White House official attacks Bristol over Medicare price talks
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Vertex pushes a donation program to widen access to cystic fibrosis treatments, but advocates say it’s not enough
Vertex Pharmaceuticals is being accused by a group of advocates and physicians of refusing to…
Today’s biotech news roundup, in under 800 words
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: More U.S. states and cities are suing insulin makers; Biden looks to boost U.S. drug manufacturing amid shortages
Top of the morning to you, and a fine one it is. Cool breezes and…
STAT+: A growing number of U.S. states, cities, and counties are suing insulin makers and PBMs
In response to strained budgets, a growing number of state and local governments across the…
STAT+: Most clinical trials run in Canada failed to take basic steps toward transparency, analysis finds
Just 3% of more than 3,700 studies run exclusively in Canada over a recent 10-year…
STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market
Good morning, everyone, and nice to see you again after an extended break on this…
A new algorithm unveils CRISPR ‘treasure trove’
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Sales of antibiotics for food-producing animals dropped by more than half in Europe over the past decade
Amid concerns over the use of medically important antibiotics given to food-producing livestock, sales of…
.jpg)
Medtronic isn’t afraid of Wegovy’s potential to disrupt
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Pharmalittle: European patent agency invalidates a Moderna mRNA patent; pharma ally Eshoo plans to retire
Good morning! This is Jonathan Wosen, West Coast biotech and life sciences reporter, filling in…
Bayer’s new CEO was dealt a duo of ‘clearing events.’ Tough choices lie ahead
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Texas sues Pfizer over ADHD drugs; Merck buys a neuro startup
Hello, everyone. Damian Garde here, filling in for Ed Silverman on what is an abbreviated…
STAT+: Delay of eye drop recall highlights FDA’s impotence on the issue
WASHINGTON — It took nearly three weeks for a maker of eye drops to recall…
STAT+: Pharmalittle: CRISPR pioneers reflect on future of gene editing; U.K. and pharma reach deal on how NHS pays for drugs
Good morning and welcome to Thanksgiving week! STAT reporter Andrew Joseph here filling in for…
Merck cough drug doesn’t pass panel scrutiny
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: U.K., pharma industry strike deal for how the NHS pays for medicines
LONDON — The U.K. and the pharmaceutical industry have reached a deal on a five-year…
STAT+: What Eli Lilly’s Zepbound reveals about the intricate process of naming drugs today
Whether you’re a fan of the drug name Zepbound or, like one X user, think…
STAT+: Pharmalittle: Woodcock to retire from the FDA; Acrotech urged to speed up confirmatory study of cancer drugs
And so, another working week will soon draw to a close Not a moment too…
STAT+: FDA cites Dr. Reddy’s for quality control problems at a biologics plant
Dr. Reddy’s Laboratories, one of the world’s largest generic drugmakers, was cited by the U.S….
STAT+: Pharmalittle: U.K. approves world’s first CRISPR-based medicine; FDA to review pricey cancer drug lacking confirmatory data
Rise and shine, everyone, another busy day is on the way. We can tell because…
How do we know Alzheimer’s drugs ‘work’?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Bristol wins U.S. approval for lung cancer drug targeting rare genetic mutation
The Food and Drug Administration on Wednesday approved a new treatment for people with non-small…
STAT+: More drug and device patents were invalidated for bad info than those filed by other industries, analysis finds
The patents on medicines and devices approved by the U.S. Food and Drug Administration were…
STAT+: Pharmalittle: German regulator eyes Ozempic export ban amid shortages; NIH-funded clinical trials lagging pharma’s in enrollment
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: New NIH head says government has fallen behind pharma on clinical trials
WASHINGTON — The new National Institutes of Health director, Monica Bertagnolli, said it’s a “failure”…
STAT+: Pharmalittle: AMA calls for obesity drug coverage; Covid rebound may be more common with Paxlovid than without
Top of the morning to you. And a fine one it is. Lots of sunshine…
STAT+: Michigan bill that would pare back pharma liability shied law moves closer to enactment
A one-of-a-kind law in Michigan that prevents the state government and residents from suing pharmaceutical…
STAT+: Pharmalittle: Wegovy cuts heart attack risk in milestone trial; AstraZeneca prioritizes U.S. for RSV drug amid surge
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Novo Nordisk wants to be a cardiovascular company, too, with sights set on inflammation
PHILADELPHIA – Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster…
Wegovy cuts risk of heart attacks in milestone cardiovascular trial
PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in…
The first vaccine for the increasingly prevalent chikungunya virus is here
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Novo Nordisk to spend $6 billion to boost production; FDA okays world’s first vaccine for chikungunya
And so, another working week will soon draw to a close. Not a moment too…
STAT+: EU regulator recommends expanding diabetes drug Mounjaro’s approval to include obesity
LONDON — Two days after similar decisions in the U.S. and U.K., regulators in Europe…
Eli Lilly tries a rare tactic: competing on price
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Sanofi CEO defends company’s move to abandon profit guidance and boost research
LONDON — Sanofi CEO Paul Hudson on Wednesday defended his company’s recent moves to abandon…
STAT+: FDA’s Califf wants to get the public as excited about life expectancy as cures
WASHINGTON — It’s easy to get people worked up about cures, but they don’t seem…